Treatment of @entity2132 after allogeneic marrow transplantation. Randomized study comparing corticosteroids and XXXX .

@entity1 @entity1667 @entity2150 @entity205 @entity2132 @entity1583
Seventy-seven @entity1 (age 12 to 46 years) who underwent allogeneic marrow transplantation for @entity1583 or @entity2150 and who had grade II to IV @entity2132 despite methotrexate prophylaxis were randomly assigned to receive @entity1667 2 mg/kg per day intravenously (n = 39) or @entity205 (n = 38) either 12 to 15 mg/kg per day orally or 3 to 5 mg/kg per day intravenously. In both groups, clinical and histologic evidence of @entity2132 was detected at medians of 16 and 25 days, respectively. Drugs were given for a minimum of 14 days unless significant deterioration occurred. If @entity2132 did not improve with this therapy, treatment with a second agent was initiated. Treatment responses were scored after reviewing clinical and laboratory data collected before, during, and after the 14-day treatment period. Possible scores were as follows: -1, worse; 0, no change; + 1, improvement in one organ system (skin, liver, gut) with no deterioration in the other two; +2, complete resolution of all involved systems. The median response score among 39 @entity1667 -treated @entity1 was 0. Sixteen @entity1 (41 percent) showed response to treatment, 11 with partial and five with complete response. The median response score among 38 @entity205 -treated @entity1 was +1. Twenty-three @entity1 (61 percent) showed response to treatment, 15 with partial and eight with complete response (p = 0.039). Twenty @entity1 receiving @entity1667 and 18 receiving @entity205 required additional therapy. The incidence of @entity2132 was similar in both groups. It developed in all nonresponding @entity1 at risk who had received secondary therapy. Among responding @entity1 (scores +1 or +2) who were not given additional treatment, @entity2132 developed in eight of 11 (72 percent) receiving @entity1667 and five of ten (50 percent) receiving @entity205 . Survival beyond 17 months was similar in the two groups (28 percent and 24 percent, respectively). These data suggest that @entity205 is a useful agent for the treatment of @entity2132 , comparable in its efficacy to @entity1667 .
